Cell imaging and picking instrument enables the selection of cells using quantitative measurements based on the pharmacological properties of affinity and specificity
Genetix has announced the launch of their next generation mammalian cell imaging and picking instrument, the ClonePixFL. The ClonePixFL adds fluorescent capabilities to the ClonePix's ability to pick antibody producing clones.
The device enables the selection of cells using quantitative measurements based on the pharmacological properties of affinity and specificity, the criteria that determine whether a drug will succeed or fail.
This approach is designed to dramatically reduce the time and cost of introducing biopharmaceutical products. Large populations of cells can be screened, significantly increasing the chance of identifying the best colonies.
Using fluorescence labels, ClonePixFL can categorise the cells and pick the superset of highest expressing colonies for subsequent downstream tissue culture.
Picking a smaller number of colonies - those which are the most productive - saves costs and shortens the development timeline.
Ian Taylor, business manager at Genetix, commented: "Through an early adoption programme we have already secured commitment for the first orders and have been very encouraged by the early interest shown from customers who expect that this technology will deliver them a competitive edge."
